A review of international coverage and pricing strategies for personalized medicine and orphan drugs
Health Policy, 2017, vol. 121, issue 12, 1240-1248
Personalized medicine and orphan drugs share many characteristics—both target small patient populations, have uncertainties regarding efficacy and safety at payer submission, and frequently have high prices. Given personalized medicine's rising importance, this review summarizes international coverage and pricing strategies for personalized medicine and orphan drugs as well as their impact on therapy development incentives, payer budgets, and therapy access and utilization.
Keywords: Precision medicine[MeSH]; Orphan drug production[MeSH]; Insurance, health, reimbursement[MeSH]; Pricing (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations Track citations by RSS feed
Downloads: (external link)
Full text for ScienceDirect subscribers only
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:121:y:2017:i:12:p:1240-1248
Access Statistics for this article
Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput
More articles in Health Policy from Elsevier
Series data maintained by Dana Niculescu ().